TL;DR
A cosmetic peptide that borrowed Argireline's first six amino acids and added two more. Sold as "better"; tested the same way.
What: An 8-amino-acid acetylated and amidated synthetic peptide (Ac-EEMQRRAD-NH₂) from Lipotec (now Grupo LUBRIZOL). INCI name Acetyl Octapeptide-3.
Does: Designed to mimic the N-terminal of SNAP-25 and competitively block SNARE complex formation at the presynaptic membrane. Reduced acetylcholine release in cell culture.
Evidence: Lipotec in-vitro and consumer-perception in-vivo work only. The "63% wrinkle-depth reduction" figure is in-vitro. No independent peer-reviewed human RCTs. Argireline has published clinical evaluation; SNAP-8 doesn't.
Used by: Cosmetic formulators at 3–10% in eye creams and anti-expression-line serums, often paired with Argireline, Matrixyl, or Leuphasyl in multi-peptide formulations.
Bottom line: Same SNARE story as Argireline, two extra amino acids, no independent trial of its own. The upgrade is structural. The proof is still Lipotec's.
What It Is
SNAP-8 is a synthetic 8-amino-acid peptide with the sequence Ac-Glu-Glu-Met-Gln-Arg-Arg-Ala-Asp-NH₂ (one-letter code Ac-EEMQRRAD-NH₂). The N-terminus is acetylated and the C-terminus is amidated — modifications that stabilize the peptide against aminopeptidase and carboxypeptidase degradation and improve formulation stability in topical products. Molecular weight is approximately 946 Da.
The INCI (International Nomenclature of Cosmetic Ingredients) name is Acetyl Octapeptide-3. An alternative name occasionally used is Acetyl Glutamyl Heptapeptide-1. The trade name SNAP-8™ is held by Lipotec (Spain), now part of Grupo LUBRIZOL. SNAP-8 was developed as a next-generation cosmetic active following Lipotec's earlier peptide Argireline® (Acetyl Hexapeptide-8, Ac-Glu-Glu-Met-Gln-Arg-Arg-NH₂), sharing Argireline's first six amino acids plus an additional Ala-Asp C-terminal extension designed to improve receptor-mimetic affinity and wrinkle-reduction efficacy.
SNAP-8's design intent is to mimic the N-terminal region of SNAP-25 (Synaptosomal-Associated Protein, 25 kDa), a presynaptic membrane protein that forms part of the SNARE complex (together with syntaxin-1 and VAMP/synaptobrevin) essential for synaptic vesicle fusion and neurotransmitter release at the neuromuscular junction. Botulinum toxin type A, the pharmacological active in Botox®, cleaves SNAP-25 at a specific site to destroy SNARE-complex formation and paralyze the affected muscle. SNAP-8 approaches the same SNARE machinery through a competitive inhibition rather than proteolytic destruction — binding the SNARE-forming partners at a mimetic site rather than destroying SNAP-25 — producing a reversible, dose-dependent attenuation of SNARE assembly rather than the long-lasting paralysis of botulinum toxin.
SNAP-8 is supplied as a synthetic peptide by Lipotec and is incorporated into topical cosmetic formulations at 3–10% concentration by multiple downstream skincare manufacturers. It also exists in research-reagent channels for in-vitro SNARE-complex research. There is no FDA-approved SNAP-8 drug product, no investigational therapeutic program, and no human clinical trial in the pharmaceutical-development sense — SNAP-8 occupies the cosmetic-ingredient regulatory pathway rather than the pharmaceutical one.
Mechanism of Action
SNAP-8's mechanism is narrowly defined as a SNARE-complex competitive inhibitor. Unlike most peptides on this site, its pharmacological target is a specific intracellular protein-protein interaction:
- SNARE complex basics — Neurotransmitter release at the neuromuscular junction and other synapses requires docking and fusion of neurotransmitter-containing synaptic vesicles with the presynaptic membrane. This fusion is driven by the SNARE complex — a four-helix bundle formed by SNAP-25 (two helices), syntaxin-1 (one helix), and VAMP/synaptobrevin (one helix). Calcium influx through voltage-gated Ca²⁺ channels during the action potential binds synaptotagmin, which then catalyzes the SNARE-mediated fusion event. SNARE complex formation is the rate-limiting molecular step in neurotransmitter release.
- SNAP-25 N-terminus mimicry — SNAP-8's sequence corresponds to the N-terminal region of SNAP-25. In competitive in-vitro SNARE-complex assembly assays, SNAP-8 occupies a binding site on the partner SNARE proteins, preventing endogenous SNAP-25 from engaging productively. Reduced SNARE complex formation → reduced vesicle fusion → reduced acetylcholine release at the neuromuscular junction → attenuated muscle contraction.
- Competitive rather than proteolytic — The mechanism is reversible. Unlike botulinum toxin, which irreversibly cleaves SNAP-25 via its protease activity, SNAP-8's competitive binding is displaced when SNAP-8 dissociates or is degraded, allowing normal SNARE assembly to resume. This gives SNAP-8 a theoretically more controllable pharmacological profile but also a substantially weaker effect size than proteolytic botulinum toxin.
- Reduced neurotransmitter release → attenuated muscle contraction — In cell-culture models of neuromuscular junction preparations, SNAP-8 reduces evoked acetylcholine release. Translated to cosmetic application, the claim is reduced contraction of small facial expression muscles (procerus, corrugator supercilii, orbicularis oculi) that drive dynamic wrinkles like glabellar lines and crow's feet.
- Topical penetration — As a hydrophilic cationic 8-mer of ~946 Da, SNAP-8 sits at the upper edge of the conventional ~500 Da molecular-weight ceiling for passive stratum corneum penetration. Topical formulation typically uses penetration-enhancing vehicles (liposomes, lipid nanoparticles, glycerin/propylene glycol) to support adequate dermal delivery. Pintea et al. 2023 and others have studied controlled-release nanoparticle delivery to increase efficiency.
- No systemic bioavailability — From topical application at cosmetic concentrations, systemic absorption of intact SNAP-8 is minimal to undetectable. The mechanism is restricted to local dermal / neuromuscular effects at the application site. This is an important safety feature — it limits the risk of systemic SNARE inhibition that could theoretically affect off-target neuromuscular junctions.
- Comparison to Argireline — In head-to-head in-vitro studies, SNAP-8 reportedly outperforms Argireline by approximately 30% in wrinkle-depth reduction and muscle-contraction inhibition, supporting its positioning as a "next-generation" cosmetic neuropeptide. Independent peer-reviewed confirmation of this head-to-head claim is limited.
- Reversibility and half-life — Topical SNAP-8 effect is transient (hours to days); twice-daily topical application is the standard cosmetic protocol to maintain effect. There is no long-term "accumulation" mechanism.
What the Research Shows
SNAP-8 has a narrow published evidence base, entirely within the cosmetic-ingredient research paradigm rather than pharmaceutical drug development:
- Lipotec manufacturer in-vitro studies — Original in-vitro SNARE-complex assembly assays demonstrated competitive inhibition by SNAP-8, with IC50 values in the micromolar range. These studies form the mechanistic foundation for cosmetic marketing but were not peer-reviewed independent pharmacological characterization.
- Manufacturer in-vivo cosmetic studies — Lipotec-sponsored in-vivo studies reported ~21% wrinkle-smoothing and 15–20% wrinkle-depth reduction at 4% SNAP-8 over 28 days, with wrinkle-smoothing evident in 80% of subjects and wrinkle reduction in 73%. Maximum reported reduction ~52% in selected subjects. These are cosmetic-industry consumer-perception and image-analysis studies, not pharmaceutical Phase 2 / 3 trials.
- Jung JH et al. Journal of Analytical Science and Technology 2020 — Method development paper for acetyl octapeptide-3 analysis by liquid chromatography–tandem mass spectrometry. Primarily analytical rather than pharmacodynamic, but establishes quantification methodology for regulatory and formulation work.
- Computational / molecular modeling studies — Pintea et al. and others have published molecular dynamics and docking studies characterizing SNAP-8 binding to the SNARE complex and to synaptotagmin, supporting the mechanistic hypothesis without providing independent in-vivo efficacy confirmation.
- Nanoparticle delivery studies — Several formulation-chemistry papers have explored nanoparticle-encapsulated SNAP-8 as a controlled-release delivery strategy to enhance dermal penetration and residence time. These are formulation-optimization studies rather than efficacy trials.
- No independent head-to-head trials with botulinum toxin — No peer-reviewed independent study has directly compared topical SNAP-8 to injected botulinum toxin A. Manufacturer and marketing materials present favorable comparisons, but these are framed as alternative modalities rather than demonstrated therapeutic equivalents. Clinically, injected botulinum toxin at typical aesthetic doses produces substantially greater and longer-lasting wrinkle reduction than topical SNAP-8 ever can.
- No pharmaceutical Phase 1/2/3 trials — SNAP-8 has no IND and no clinical-trials.gov registered protocols. It exists exclusively in the cosmetic-ingredient regulatory pathway.
Critical Context — "Botox-Alternative" Marketing Overstates Effect Size
SNAP-8 is a legitimate topical cosmetic ingredient with a documented mechanism. But the "botox-alternative" marketing substantially overstates the functional comparison. Injected botulinum toxin A at aesthetic doses produces 50–90% reduction in glabellar-line severity for 3–4 months; topical SNAP-8 at 4–10% in formulation produces 15–20% reduction in wrinkle-depth metrics over 28 days of twice-daily application. These are not equivalent interventions — they share a target (SNARE / SNAP-25) but differ by orders of magnitude in clinical effect. Consumer-marketing framing of SNAP-8 as a "botox alternative" is accurate as a conceptual target description and inaccurate as a clinical-effect comparison.
Human Data
SNAP-8 human data is exclusively from manufacturer-sponsored cosmetic-industry in-vivo studies and consumer-perception research. There are no pharmaceutical clinical trials.
- Manufacturer in-vivo studies — Lipotec in-vivo studies on volunteers using 4% SNAP-8 in cosmetic emulsion over 28 days report:
- • 21% skin-smoothing improvement vs baseline
- • 15–20% wrinkle-depth reduction vs baseline
- • Maximum wrinkle-depth reduction 52% in selected responders
- • Effect measurable in ~80% of volunteers
- • Wrinkle-reduction effect in ~73% of volunteers
- Manufacturer comparison to Argireline — Side-by-side in-vivo studies report SNAP-8 ~30% more effective than equivalent concentration of Argireline (Acetyl Hexapeptide-8) for wrinkle-depth reduction, supporting the "next-generation" marketing claim.
- Independent peer-reviewed human trials — None published. The Jung 2020 method-development paper and computational modeling studies do not constitute efficacy evidence.
- Consumer-perception surveys — Large-scale consumer surveys through cosmetic-industry channels report generally favorable user satisfaction, but these are consumer ratings rather than controlled clinical outcome measures.
- No injection trials — No injected SNAP-8 trial has been conducted in humans for any indication. There is no pharmacological rationale for injection (systemic SNARE inhibition is neither achievable nor desirable at community doses), and no safety data supports injection use.
- Pediatric / pregnancy data — No specific pediatric or pregnancy trials. As a topical cosmetic ingredient used in general adult anti-aging applications, use during pregnancy and in pediatric populations is not routinely recommended.
Dosing from the Literature
SNAP-8 dosing is entirely within the cosmetic-topical paradigm. No injected or oral dose exists in published literature:
| Context | Concentration / Dose | Route | Notes |
|---|
| Manufacturer recommended cosmetic use | 3–10% in finished formulation | Topical twice daily | Lipotec recommended range for anti-wrinkle serums, creams, and eye products. |
| Lipotec in-vivo 28-day study | 4% in vehicle | Topical twice daily × 28 days | Vehicle was aqueous cosmetic emulsion; penetration enhanced with glycerin/propylene glycol. |
| High-concentration consumer serums | Up to 10% | Topical twice daily | Higher concentrations used in premium anti-aging skincare products. |
| Nanoparticle-formulated | Lower equivalent load (1–3%) | Topical | Controlled-release nanoparticles allow reduced peptide concentration for equivalent or enhanced effect. |
| In-vitro SNARE inhibition IC50 | Low micromolar | Cell culture | Laboratory research concentration; not applicable to human use. |
| Injection dose | None established | — | Injection is not the intended route, has no safety data, and has no pharmacological rationale at community doses. |
Dosing Disclaimer
SNAP-8 is a topical cosmetic ingredient. The only legitimate use route is topical application at 3–10% concentration in cosmetic formulations, twice daily. Injected or oral SNAP-8 has no published safety or efficacy data, no pharmacological rationale at community doses, and no place in community peptide protocols. Consumer framing of SNAP-8 as a "botox injection alternative" refers to topical application, not to injection of SNAP-8 itself.
Reconstitution & Storage
SNAP-8 is supplied by Lipotec and research-reagent vendors as raw peptide for formulation:
| Form | Typical Quantity | Use Context | Storage |
|---|
| Finished cosmetic product (consumer) | 30–100 mL serum / cream | Topical cosmetic | Room temperature; product shelf life 12–24 months |
| Raw peptide (formulators) | 1 g – 1 kg synthesis batches | Industrial formulation | 2–8°C or −20°C long-term; desiccated |
| Research-reagent vial (in-vitro use) | 1–10 mg vial | Laboratory research | −20°C lyophilized; −80°C reconstituted aliquots |
| Aqueous topical solution (DIY) | Variable concentration | Consumer formulation | Refrigerate; short shelf life without preservative system |
- Solubility — SNAP-8 is water-soluble; formulates readily into aqueous cosmetic emulsions, gels, and serums. The N-terminal acetyl group and C-terminal amide group improve stability vs aminopeptidase / carboxypeptidase degradation.
- Formulation pH — Stable across the cosmetic-typical pH range 4–7. Avoid strongly acidic or alkaline formulations for prolonged storage.
- Penetration enhancement — At ~946 Da, SNAP-8 benefits from penetration-enhancing vehicle chemistry (liposomes, lipid nanoparticles, glycerin, propylene glycol). Aqueous-only vehicles produce limited dermal delivery.
- Storage — Raw peptide stable at −20°C for 2+ years. Finished cosmetic products follow normal skincare shelf-life considerations (12–24 months unopened).
- Light / oxidation — Dark or opaque packaging (amber glass, biophotonic glass) is recommended to protect peptide integrity from UV / visible light degradation.
Side Effects & Risks
Important
Topical cosmetic use only, no injectable pathway. Loop your physician in before pairing SNAP-8 with botulinum-toxin treatments — cell-culture SNARE inhibition doesn't equal in-vivo muscle paralysis.
SNAP-8 has a benign safety profile in topical cosmetic use, consistent with its narrow mechanism and minimal systemic absorption:
- Mild topical reactions — Occasional redness, itching, or irritation at application sites, typically related to other formulation components (preservatives, fragrance) rather than SNAP-8 itself. Self-limiting.
- Rare hypersensitivity — As a synthetic peptide, hypersensitivity reactions are uncommon but possible. Patch testing recommended for sensitive skin before broad facial application.
- No systemic effects at topical cosmetic doses — Systemic absorption is minimal; no documented systemic neuromuscular effects from topical cosmetic use at 3–10% concentration.
- Pregnancy and lactation — No specific safety data. Topical cosmetic use is not explicitly contraindicated but pregnant women often choose to limit peptide and "botox-like" product use during pregnancy.
- Pediatric — Not appropriate; anti-wrinkle peptides are not designed for pediatric skin.
- Sun / heat stability — The peptide itself is stable within normal product use but avoid extreme heat (closed car in summer). UV degradation is reduced by proper packaging.
- Drug interactions — Minimal for topical use. Concurrent topical retinoids, alpha-hydroxy acids, and strong actives may share vehicles but do not chemically interact with SNAP-8 in meaningful ways.
- Injection (community, off-label) — SNAP-8 is not designed for injection. There is no safety data for injected SNAP-8, no pharmacological rationale at community doses (systemic SNARE inhibition is neither achievable nor desirable), and no community protocol should recommend injection use. Any injected SNAP-8 should be regarded as entirely experimental and unsupported.
- Quality / sourcing — For cosmetic use, purchase finished products from established skincare brands with documented formulation chemistry. For research-reagent use, independent third-party Certificate of Analysis (HPLC purity ≥98%, mass-spec confirmation of acetylation and amidation) is the floor.
Bloodwork & Monitoring
None required for topical cosmetic use. Standard skincare practice applies:
- Patch test — Apply to a small inconspicuous area (inner forearm, behind ear) before full facial application, particularly for sensitive skin.
- Dermatologic evaluation — For any persistent irritation, rash, or unusual skin reaction, discontinue use and consult a dermatologist.
- Photography tracking — For users tracking cosmetic efficacy, standardized before / 4-week / 8-week photographs at matched lighting and angle provide the most useful personal evidence (subjective memory for cosmetic changes is unreliable).
- No systemic bloodwork — Topical cosmetic use does not require serum or metabolic monitoring.
Commonly Stacked With
SNAP-8 is typically layered within a broader topical skincare regimen:
Argireline (Acetyl Hexapeptide-8)
Lipotec's earlier-generation SNARE-mimetic peptide (6 amino acids, N-terminal portion of SNAP-25). Some formulations stack SNAP-8 with Argireline for complementary SNARE-targeting. The benefit of stacking two mechanism-similar peptides over using SNAP-8 alone at a higher concentration is not well-established.
Matrixyl (Palmitoyl Pentapeptide-4)
Collagen-stimulating peptide (different mechanism). Complementary to SNAP-8 — SNAP-8 addresses dynamic wrinkles from muscle contraction, Matrixyl addresses static wrinkles from collagen loss. Common combination in anti-aging formulations.
Topical copper-peptide used for collagen synthesis, wound healing, and skin quality. Mechanism-distinct from SNAP-8. Combined in layered anti-aging topical regimens — SNAP-8 for expression lines, GHK-Cu for collagen / ECM.
Retinol / Retinoids
Vitamin A derivatives with the strongest evidence-based anti-aging skincare effect. Mechanism-distinct from SNAP-8. Standard layered regimen: SNAP-8 AM, retinoid PM, or alternate-day protocols. Some vehicle chemistry requires formulation considerations.
Hyaluronic acid / glycerin humectants
Moisture retention. Complementary to SNAP-8's neuromuscular mechanism; does not interfere with peptide activity.
→ Check compound compatibility in the Stack Builder
Regulatory Status
Current Status — April 2026
SNAP-8 (Acetyl Octapeptide-3) is regulated as a cosmetic ingredient rather than a pharmaceutical. It is listed in the International Nomenclature of Cosmetic Ingredients (INCI) dictionary under "Acetyl Octapeptide-3" and is approved for cosmetic use in the United States, European Union, United Kingdom, Australia, Japan, Korea, and most other major jurisdictions under their respective cosmetic-ingredient regulatory frameworks.
SNAP-8 is not an FDA-approved drug for any indication. No IND application has been filed, no clinical trials are registered, and no pharmaceutical development program is active. Its regulatory pathway is exclusively the cosmetic-ingredient pathway.
SNAP-8 is not on the FDA Category 2 Bulk Drug Substances list and is therefore not part of HHS Secretary Robert F. Kennedy Jr.'s February 2026 reclassification announcement. The peptide compounding framework does not apply to cosmetic ingredients. U.S. compounding pharmacies cannot legally compound SNAP-8 as a pharmaceutical; the legitimate supply pathway is through cosmetic-ingredient channels to finished-product manufacturers.
SNAP-8 is not specifically named on the WADA Prohibited List. As a topical cosmetic ingredient with negligible systemic absorption, it does not have a realistic anti-doping concern for competitive athletes.
In EU cosmetic regulation, SNAP-8 is subject to standard EC 1223/2009 Cosmetic Products Regulation requirements including safety assessment, product notification, and labeling. In the United States, SNAP-8-containing cosmetics are regulated under the FDA Modernization of Cosmetics Regulation Act (MoCRA 2022). Neither regulatory framework involves pharmaceutical-grade clinical efficacy evidence — cosmetic regulation is primarily safety-focused, allowing manufacturer claims framed as cosmetic benefits rather than therapeutic effects.
Cost & Access
SNAP-8 is not approved for human use as a pharmaceutical. It is available through research suppliers for laboratory research purposes only, and through cosmetic-ingredient supply chains to finished-product skincare manufacturers.
Consumer access to SNAP-8 is through finished cosmetic products — anti-aging serums, creams, and eye products marketed by multiple skincare brands. These are legal consumer cosmetics, not pharmaceutical products, and operate under cosmetic-regulation frameworks in their respective jurisdictions.
U.S. compounding pharmacies cannot legally compound SNAP-8 as a pharmaceutical under current FDA rules — it has no FDA-approved pharmaceutical reference product and is not a recognized 503A bulk ingredient. Research-reagent vendors supply synthetic peptide for laboratory use at variable purity and pricing; independent third-party Certificate of Analysis (HPLC purity ≥98%, mass-spec confirmation of acetylation and amidation) is essential for research quality.
SNAP-8 is not currently among the peptides under HHS Secretary Robert F. Kennedy Jr.'s February 2026 Category 2 reclassification announcement. As a cosmetic ingredient rather than a peptide drug candidate, it falls outside the pharmaceutical compounding framework entirely.
Estimated pricing as of April 2026. Actual costs vary by provider, location, and prescription status. Kalios does not sell compounds.
Related Compounds
Cosmetic peptides in the same SNARE- or neuromuscular-mimetic category:
Acetyl hexapeptide-8. SNAP-25-targeting cosmetic peptide that reduces expression-line formation.
Dipeptide diaminobutyroyl benzylamide diacetate. Synthetic snake-venom mimic that relaxes facial muscle contraction.
Palmitoyl pentapeptide-4. The original collagen-stimulating cosmetic peptide. Drives type I and III collagen synthesis.
Pentapeptide-3. Acetylcholine-receptor-blocking cosmetic peptide that relaxes facial muscle tone.
Palmitoyl tripeptide-5. Collagen-stimulating cosmetic peptide mimicking TSP-1 activation of latent TGF-β.
Key References
- Lipotec S.A. / Grupo LUBRIZOL. SNAP-8™ (Acetyl Octapeptide-3) product documentation and in-vivo manufacturer studies. (Foundational in-vitro SNARE-complex characterization and 4% / 28-day in-vivo cosmetic efficacy data — industry sponsor documentation.)
- Jung JH, Ji JY, Kim JW, Kim DY, Lim HJ, Lee HS, Jin JS, Kim YS. Method development for acetyl octapeptide-3 analysis by liquid chromatography-tandem mass spectrometry. J Analytical Sci Technol. 2020;11(1):25. (Analytical method development for quantifying SNAP-8 in cosmetic formulations.)
- Pintea A, Manea A, Pintea C, Vlad RA, Bîrsan M, Antonoaea P, Rédai EM, Ciurba A. New insight into anti-wrinkle treatment: Using nanoparticles as a controlled release system to increase acetyl octapeptide-3 efficiency. (Nanoparticle-delivery optimization study.)
- Molecular modeling elucidates the cellular mechanism of synaptotagmin-SNARE inhibition: a novel plausible route to anti-wrinkle activity of botox-like cosmetic active molecules. (Computational binding characterization.)
- Sudhof TC, Rothman JE. Membrane fusion: grappling with SNARE and SM proteins. Science. 2009;323(5913):474-477. PMID: 19164740. (Foundational SNARE-complex biology — Nobel Prize context for the mechanism SNAP-8 targets.)
- Jahn R, Fasshauer D. Molecular machines governing exocytosis of synaptic vesicles. Nature. 2012;490(7419):201-207. PMID: 23060190. (SNARE-complex mechanistic review.)
- Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002;24(5):303-310. PMID: 18498522. (Argireline characterization — direct predecessor to SNAP-8.)
- Wang Y, Wang M, Xiao XS, Huo J, Zhang WD. The anti-wrinkle efficacy of Argireline. J Cosmet Laser Ther. 2013;15(4):237-241. PMID: 23472662. (Argireline efficacy data providing comparator context for SNAP-8.)
- Dong L, Liu W, Bai X, et al. Molecular modelling of synaptotagmin-SNARE protein-protein interactions and implications for rational SNARE-targeted peptide design. (Computational anti-wrinkle peptide mechanistic study.)
- Montal M. Botulinum neurotoxin: a marvel of protein design. Annu Rev Biochem. 2010;79:591-617. PMID: 20233039. (Botulinum toxin / SNAP-25 mechanism — comparator framework for SNAP-8.)
- Dressler D, Benecke R. Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil. 2007;29(23):1761-1768. PMID: 18033603. (Injected botulinum toxin clinical pharmacology — comparator for SNAP-8 topical claims.)
- Draelos ZD. Cosmeceuticals: topical anti-aging products. Postgrad Med. 2007;119(1):66-73. (Cosmetic anti-aging peptides review.)
- Resende DISP, Ferreira M, Magalhães C, Sousa Lobo JM, Sousa E, Almeida IF. Trends in the use of marine ingredients in anti-aging cosmetics. Algal Res. 2021;55:102273. (Cosmetic peptide landscape context.)
- Ruiz MA, Clares B, Morales ME, Cazalla S, Gallardo V. Preparation and stability of cosmetic formulations with an anti-aging peptide. J Cosmet Sci. 2007;58(2):157-171. PMID: 17520181. (Cosmetic formulation chemistry for peptide actives.)
- Zhang Y, Xu Q, Zhuang C. Synthesis and preliminary evaluation of the anti-wrinkle effect of acetyl octapeptide-3 (SNAP-8). Chin J Dermatol. 2016;49(8):593-596. (Chinese dermatology journal report on SNAP-8 — one of the few peer-reviewed non-manufacturer SNAP-8 studies.)
- European Commission Cosmetic Ingredient Database (CosIng). Acetyl Octapeptide-3. ec.europa.eu. (EU cosmetic-ingredient regulatory listing.)
- Personal Care Products Council INCI Dictionary. Acetyl Octapeptide-3. (INCI nomenclature and standard cosmetic-ingredient classification.)
- FDA. Modernization of Cosmetics Regulation Act (MoCRA). fda.gov. 2022. (U.S. cosmetic-regulation framework applicable to SNAP-8-containing products.)
- EC Cosmetic Products Regulation 1223/2009. (EU cosmetic-regulation framework.)
- PubChem CID 60210007. Acetyl octapeptide-3 (SNAP-8). (Structural and physicochemical reference.)
Last updated: April 2026 | Profile authored by Kalios Peptides research team